|
Mutation Information
|
Mutation Site
|
M184I |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Relevant Drug
|
dolutegravir (DTG);raltegravir (RAL) |
|
Country
|
Europe;Sub‐Saharan Africa;South America;Middle East;South‐east Asia |
Literature Information
|
PubMed PMID
|
32964671
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2021 |
|
Journal
|
HIV medicine |
|
Title
|
Transmitted drug resistance to NRTIs and risk of virological failure in naïve patients treated with integrase inhibitors. |
|
Author
|
Borghetti A,Ciccullo A,Lombardi F,Baldin G,Belmonti S,Prosperi M,Incardona F,Heger E,Borghi V,Sönnerborg A,Zazzi M,De Luca A,Di Giambenedetto S |
|
Evidence
|
However, the presence of M184V/I independently predicted VF of raltegravir- but not dolutegravir-based therapy when compared with a fully-active backbone [adjusted hazard ratio (aHR) = 3.09, P = 0.035], particularly when associated with other non-thymidine analogue mutations (aHR = 27.62, P = 0.004).
|
|
|
HIV Mutation Detail Information